American Diversified Holdings Operating Division GlucoGuard Retains Global Contract Research Organization (CRO) to Begin Patient Studies as Required by the FDA

CRO to Incorporate DEXCOM's Continuous Glucose Monitoring "CGM" Technology In the GlucoGuard Multi Patient Study Del Mar, California--(Newsfile Corp. - April 1, 2026) - American Diversified Holdings Corporation (OTCID: ADHC) announce today that GlucoGuard has retained a internationally recognized Contract Research Organization (CRO) to begin its patient studies to establish safety and efficacy concerns as required by the FDA. The Scope of Work agreement will comply with the FDA's requests to gain approval.